GeneDx Holdings Corp.

GeneDx Holdings Corp., trading under the ticker CMLF, is a healthcare-focused special purpose acquisition company associated with CM Life Sciences III, sponsored by entities affiliated with Casdin Capital and Corvus Capital Partners. The vehicle completed its initial public offering in 2021 and targeted the genomics and precision medicine sector. The 10-Q filing dated May 24, 2021, with accession number 0001213900-21-028608, reflects the company's quarterly reporting obligations during its operational phase as a publicly traded blank-check company. GeneDx, the target business, is a clinical genomics and genetic testing company focused on rare disease diagnostics. Sign up on SpacDesk for full filing history, sponsor profiles, and real-time status updates on CMLF and every active SPAC in the market.